Earned Wealth Advisors LLC Sells 2,082 Shares of Pfizer Inc. $PFE

Earned Wealth Advisors LLC lowered its stake in Pfizer Inc. (NYSE:PFE) by 15.8% during the second quarter, HoldingsChannel.com reports. The institutional investor owned 11,057 shares of the biopharmaceutical company’s stock after selling 2,082 shares during the period. Earned Wealth Advisors LLC’s holdings in Pfizer were worth $268,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently added to or reduced their stakes in the stock. Simon Quick Advisors LLC boosted its position in Pfizer by 21.2% in the second quarter. Simon Quick Advisors LLC now owns 32,806 shares of the biopharmaceutical company’s stock valued at $795,000 after buying an additional 5,731 shares in the last quarter. Strs Ohio boosted its position in Pfizer by 9.1% in the second quarter. Strs Ohio now owns 2,150,713 shares of the biopharmaceutical company’s stock valued at $52,133,000 after buying an additional 178,799 shares in the last quarter. Adell Harriman & Carpenter Inc. boosted its position in Pfizer by 40.5% in the second quarter. Adell Harriman & Carpenter Inc. now owns 209,311 shares of the biopharmaceutical company’s stock valued at $5,074,000 after buying an additional 60,326 shares in the last quarter. Atria Investments Inc boosted its position in Pfizer by 18.9% in the second quarter. Atria Investments Inc now owns 375,544 shares of the biopharmaceutical company’s stock valued at $9,103,000 after buying an additional 59,750 shares in the last quarter. Finally, Savvy Advisors Inc. boosted its position in Pfizer by 11.6% in the second quarter. Savvy Advisors Inc. now owns 27,931 shares of the biopharmaceutical company’s stock valued at $677,000 after buying an additional 2,906 shares in the last quarter. Institutional investors and hedge funds own 68.36% of the company’s stock.

Analyst Ratings Changes

A number of analysts have weighed in on PFE shares. UBS Group restated a “neutral” rating and issued a $28.00 target price on shares of Pfizer in a research report on Wednesday, October 1st. Sanford C. Bernstein reissued a “market perform” rating and issued a $30.00 price objective on shares of Pfizer in a research note on Friday. Weiss Ratings restated a “hold (c-)” rating on shares of Pfizer in a report on Wednesday, October 8th. Morgan Stanley cut their target price on Pfizer from $33.00 to $32.00 and set an “equal weight” rating on the stock in a report on Friday, October 10th. Finally, Citigroup increased their price target on Pfizer from $25.00 to $26.00 and gave the company a “neutral” rating in a research note on Wednesday, August 6th. One analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, twelve have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $28.24.

Pfizer Price Performance

PFE stock opened at $24.68 on Friday. The firm has a market cap of $140.29 billion, a price-to-earnings ratio of 13.13, a PEG ratio of 0.81 and a beta of 0.55. The company has a quick ratio of 0.85, a current ratio of 1.16 and a debt-to-equity ratio of 0.65. Pfizer Inc. has a 12-month low of $20.92 and a 12-month high of $28.64. The company’s fifty day simple moving average is $24.77 and its 200 day simple moving average is $24.27.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.58 by $0.20. The business had revenue of $14.65 billion for the quarter, compared to analyst estimates of $13.43 billion. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. Pfizer’s revenue for the quarter was up 10.3% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.60 earnings per share. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. On average, analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, December 1st. Investors of record on Friday, November 7th will be issued a $0.43 dividend. The ex-dividend date is Friday, November 7th. This represents a $1.72 annualized dividend and a yield of 7.0%. Pfizer’s payout ratio is presently 91.49%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.